Alkermes plc (ALKS) - Stock Analysis
Last updated: Apr 5, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Sleep/psychiatry platform with newly de-risked pipeline: FDA Breakthrough Therapy designation and the launch of the Brilliance Phase 3 program for alixorexton plus the Avadel (LUMRYZ) acquisition, backed by >$1.1B cash and strong FCF, have driven ~20% 21-day price gains and position the stock for further short-term upside if momentum above ~$35 holds.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margin ⢠Strong free cash ⢠High operating expense ALKS pairs very high gross margins, strong free cash flow and a netâcash, lowâleverage balance sheet with material operating expenses, an accumulated deficit and workingâcapital concentration that increase execution and seasonality risk.
Price Behavior
Key Price Behavior Insights: ⢠Strong short-term rally ⢠Mean-reversion risk ⢠Event-driven volatility Support Level: $29.00â$30.50 Resistance Level: $35.36 ALKS is in a clear short-term uptrend trading around $34.84 (~18.8% above last month's SMA ~$29.33) with immediate resistance at $35.36âfailure to clear it would likely lead to consolidation toward support at $29.00â$30.50.
Sentiment & News
Key News Insights: ⢠Phase 3 start ⢠Mixed sentiment ⢠Share pressure Alkermes launched Phase 3 alixorexton trials and investor outreach even as mixed analyst ratings, stake trimming and short-term share weakness amid acquisition/downside chatter cloud near-term outlook.
AI Summary
Alkermes has shifted from a cashâflowing commercial play to a binary, growthâbyâdevelopment story where Phase 3 success for oral alixorexton (and clean Avadel/LUMRYZ integration) is the primary value driverâif trials and commercialization execution hit, upside is material; if not, equity will reprice sharply. Actionable: monitor Phase 3 enrollment/safety readouts, LUMRYZ revenue realization, grossâtoânet cadence, and R&D burn as the decisive nearâterm catalysts.
Description
Alkermes plc is a Dublin-based biopharmaceutical company that develops and commercializes medicines for psychiatric and neurological disorders and has operations in the United States, Ireland and other markets. Its commercial portfolio includes long-acting injectable and oral treatments for schizophrenia, bipolar disorder and substance-use disorders, as well as a product for relapsing forms of multiple sclerosis. The company maintains a pipeline that includes an oral atypical antipsychotic candidate and an engineered immunotherapy for oncology, and it holds collaboration agreements with Janssen entities.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 2 | Apr 9 | ALKS | Alkermes plc | Sleep/psychiatry platform with newly de-risked pipeline: FDA Breakthrough Therapy designation and the launch of the Brilliance Phase 3 program for alixorexton plus the Avadel (LUMRYZ) acquisition, backed by >$1.1B cash and strong FCF, have driven ~20% 21-day price gains and position the stock for further short-term upside if momentum above ~$35 holds. | Closed | +0.2% |